roche glp-1 Carmot Therapeutics Roche GLP-1 produces “robust” weight
Description
Chow vehicle (n=10)
However, current human evidence is derived mainly from metabolic trials and pharmacoepidemiologic studies conducted at approved therapeutic doses, rather than from oncology trials specifically designed to induce tumor apoptosis (174-176)
The authors have presented current strategies based on available literature adapted from the CAS and the ASA
So the review reframes where the opportunity is
In short, liraglutide, GLP-1 receptor agonist, has a direct effect on atherosclerosis lesion formation via promoting pro-resolving M2 macrophages phenotype
